4-hydroxy-piperidine derivatives
    62.
    发明授权
    4-hydroxy-piperidine derivatives 失效
    4-羟基 - 哌啶衍生物

    公开(公告)号:US06359138B1

    公开(公告)日:2002-03-19

    申请号:US08976540

    申请日:1997-11-24

    IPC分类号: C07D40106

    摘要: The present invention relates to 4-hydroxy-piperidine derivatives of the general formula wherein X denotes —O—, —NH—, —CH2—, —CH═, —CHOH—, —CO—, —S—, —SO— or —SO2—; R1-R4 are, independently from each other, hydrogen, hydroxy, lower-alkyl-sulfonylamino, 1- or 2-imidazolyl or acetamido; R5-R8 are, independently from each other, hydrogen, hydroxy, lower-alkyl, halogen, lower-alkoxy, trifluoromethyl or trifluoromethyloxy; a and b may be a double bond, provided that when “a” is a double bond, “b” cannot be a double bond; n is 0-2; m is 1-3; p is 0 or 1 and to pharmaceutically acceptable addition salts thereof. Compounds of the present invention are NMDA(N-methyl-D-aspartate)-receptor subtype selective blockers, which can be used in mediating processes underlying development of CNS including learning and memory formation and function.

    摘要翻译: 本发明涉及通式为Ⅳ的4-羟基 - 哌啶衍生物,其中X表示-O - , - NH - , - CH 2 - , - CH =, - CHOH-, - CO - , - S - , - SO-或-SO 2 - ; R 1 -R 4彼此独立地为氢,羟基,低级 - 烷基 - 磺酰基氨基,1-或2-咪唑基或乙酰氨基; R5-R8彼此独立地为氢,羟基,低级 - 烷基,卤素 低级烷氧基,三氟甲基或三氟甲氧基; a和b可以是双键,条件是当“a”是双键时,“b”不能是双键; n是0-2; m是1-3; p是0或1,以及其药学上可接受的加成盐。本发明的化合物是NMDA(N-甲基-D-天冬氨酸) - 受体亚型选择性阻断剂,其可用于介导中枢神经系统发育的过程,包括学习和记忆形成 和功能。

    N-(3-(2-AMINO-6,6-DIFLUORO-4,4A,5,6,7,7A-HEXAHYDRO-CYCLOPENTA[E][1,3]OXAZIN-4-YL)-PHENYL-AMIDES AS BACE1 INHIBITORS
    64.
    发明申请
    N-(3-(2-AMINO-6,6-DIFLUORO-4,4A,5,6,7,7A-HEXAHYDRO-CYCLOPENTA[E][1,3]OXAZIN-4-YL)-PHENYL-AMIDES AS BACE1 INHIBITORS 有权
    N-(3-(2-氨基 - 6,6-二氟-4,4A,5,6,7,7a-十六氢 - 环戊二烯并[E] [1,3]氧杂-4-基) - 苯甲酰胺 BACE1抑制剂

    公开(公告)号:US20130072478A1

    公开(公告)日:2013-03-21

    申请号:US13609304

    申请日:2012-09-11

    CPC分类号: C07D413/12

    摘要: The present invention provides N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-4-yl)-phenyl)-amides of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.

    摘要翻译: 本发明提供N-(3-(2-氨基-6,6-二氟-4,4a,5,6,7,7a-六氢 - 环戊二烯并[e] [1,3]恶嗪-4-基) - 苯基) - 具有BACE1抑制活性的式I的酰胺,其制备,含有它们的药物组合物及其作为治疗活性物质的用途。 本发明的活性化合物可用于例如治疗和/或预防性治疗。 阿尔茨海默氏病。

    Radiolabelled inhibitors of the glycine 1 transporter
    66.
    发明授权
    Radiolabelled inhibitors of the glycine 1 transporter 有权
    甘氨酸1转运蛋白的放射性标记抑制剂

    公开(公告)号:US08153679B2

    公开(公告)日:2012-04-10

    申请号:US12607111

    申请日:2009-10-28

    CPC分类号: C07D405/10

    摘要: The present invention relates to novel radiolabelled inhibitors of formula I for the Glycine 1 transporter (GlyT1), useful for the labelling and diagnostic imaging of the glycine 1 transporter functionality. wherein R1 is isopropoxy or 2,2,2-trifluoro-1-methyl-ethoxy; and R2 is a radiolabelled group CH3, wherein the radionuclide is 3H or 11C. The radiolabelled compounds of formula I may be used as PET (Positron Emission Tomography) radiotracer for the labelling and diagnostic molecular imaging of the glycine 1 transporter functionality.

    摘要翻译: 本发明涉及用于甘氨酸1转运蛋白(GlyT1)的式I的新型放射性标记抑制剂,其可用于甘氨酸1转运蛋白官能度的标记和诊断成像。 其中R1是异丙氧基或2,2,2-三氟-1-甲基 - 乙氧基; 并且R 2是放射性标记的基团CH 3,其中放射性核素是3H或11C。 放射性标记的式I化合物可用作PET(正电子发射断层扫描)放射性示踪剂,用于甘氨酸1转运蛋白功能的标记和诊断分子成像。

    Quinolizidine and indolizidine derivatives
    67.
    发明授权
    Quinolizidine and indolizidine derivatives 有权
    喹诺啶和吲哚来啶衍生物

    公开(公告)号:US08143273B2

    公开(公告)日:2012-03-27

    申请号:US13161534

    申请日:2011-06-16

    IPC分类号: A61K31/44 C07D217/02

    CPC分类号: C07D455/02 C07D471/04

    摘要: The present invention relates to a compound of formula I-A or I-B wherein X, R1, R2 and R3 are defined herein; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer thereof. The compounds of formulas I-A and I-B are good inhibitors of the glycine transporter 1 (GlyT-1), and have a good selectivity to glycine transporter 2 (GlyT-2) inhibitors, suitable in the treatment of neurological and neuropsychiatric disorders.

    摘要翻译: 本发明涉及式I-A或I-B化合物,其中X,R 1,R 2和R 3在本文中定义; 或其药学上可接受的酸加成盐,或其相应的对映异构体和/或其旋光异构体。 式I-A和I-B的化合物是甘氨酸转运蛋白1(GlyT-1)的良好抑制剂,并且对甘氨酸转运蛋白2(GlyT-2)抑制剂具有良好的选择性,适用于治疗神经和神经精神障碍。

    AMIDO-TROPANE DERIVATIVES
    68.
    发明申请
    AMIDO-TROPANE DERIVATIVES 有权
    AMIDO-TROPANE衍生物

    公开(公告)号:US20110312993A1

    公开(公告)日:2011-12-22

    申请号:US13160559

    申请日:2011-06-15

    摘要: The present invention relates to a compound of formula I wherein R1, R2 and R3 are each independently hydrogen, lower alkyl, lower alkoxy, cycloalkyl, lower alkyl substituted by halogen or S-lower alkyl; or to a pharmaceutically acceptable acid addition salt, racemic mixture, or corresponding enantiomer and/or optical isomer thereof. The compounds of formula I are good inhibitors of the glycine transporter 1 (GlyT-1), and have a good selectivity to glycine transporter 2 (GlyT-2) inhibitors. The compounds can be used in the treatment of neurological and neuropsychiatric disorders.

    摘要翻译: 本发明涉及式I化合物,其中R 1,R 2和R 3各自独立地为氢,低级烷基,低级烷氧基,环烷基,被卤素或S-低级烷基取代的低级烷基; 或其药学上可接受的酸加成盐,外消旋混合物或其相应的对映异构体和/或其光学异构体。 式I化合物是甘氨酸转运蛋白1(GlyT-1)的良好抑制剂,对甘氨酸转运蛋白2(GlyT-2)抑制剂具有良好的选择性。 该化合物可用于治疗神经和神经精神障碍。